Results 271 to 280 of about 125,098 (310)
Some of the next articles are maybe not open access.
Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
Current Opinion in Lipidology, 2007The goal of identifying subjects with metabolic syndrome is to detect those at higher risk of developing cardiovascular disease. Evidence continues to accumulate as to the superiority of apolipoprotein B and apolipoprotein A-I over the conventional lipoprotein lipids as markers of vascular risk.
Allan D, Sniderman, May, Faraj
openaire +2 more sources
Apolipoproteins A‐I and B in Obese Children
Journal of Pediatric Gastroenterology and Nutrition, 1989Body mass index (BMI), the distribution of fat, birth weight, physical fitness, apolipoproteins (apo) A‐I and B, total cholesterol (TC), and high‐density lipoprotein cholesterol (HDLC) were studied in 38 obese 10− to 11‐year‐olds in comparison to 52 age‐matched controls.
T, Sveger +3 more
openaire +2 more sources
Biochemistry, 2002
Apolipoprotein A-I(Milano) (apoA-I(Milano)) and apoA-I(Paris) are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-I(WT)). In this study,
John K, Bielicki, Michael N, Oda
openaire +3 more sources
Apolipoprotein A-I(Milano) (apoA-I(Milano)) and apoA-I(Paris) are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-I(WT)). In this study,
John K, Bielicki, Michael N, Oda
openaire +3 more sources
The promise of apolipoprotein A-I mimetics
Current Opinion in Endocrinology, Diabetes & Obesity, 2010Synthetic high-density lipoprotein (HDL) and apolipoprotein (apo) A-I mimetic peptides emulate many of the atheroprotective biological functions attributed to HDL and can modify atherosclerotic disease processes. Administration of these agents as HDL replacement or modifying therapy has tremendous potential of providing new treatments for ...
openaire +2 more sources
Pharmacology of apolipoprotein A-l
Current Opinion in Lipidology, 1997The role of HDL and its main protein component the apolipoprotein A-I as being antiatherogenic is well established. Experimental data give support for the involvement of at least three different types of mechanism: (1) the reverse cholesterol transport, (2) anti-inflammatory mechanisms and (3) antithrombotic mechanisms.
openaire +2 more sources
Apolipoprotein A-I and risk for cardiovascular diseases
Current Atherosclerosis Reports, 2006Increased concentrations of high-density lipoprotein (HDL) cholesterol have been closely associated with decreased risk of future cardiovascular disease. This protective effect of HDL has been mainly attributed to its involvement in reverse cholesterol transport.
Natalie, Khuseyinova, Wolfgang, Koenig
openaire +2 more sources
Apolipoproteins A-I and B in Kuwaiti Children
Annals of Nutrition and Metabolism, 1998To assess the relation of apolipoproteins (Apos) A-I and B (the carrier proteins for high and low density lipoprotein cholesterol, respectively) with the degree of obesity, body fat distribution, serum lipids, glucose and insulin levels, a case-control study was carried out and included 460 Kuwaiti obese children, 6–13 years old, matched by age and sex
M A, Moussa +3 more
openaire +2 more sources
Immunomagnetic Separation of Subpopulations of Apolipoprotein A-I
Mayo Clinic Proceedings, 1994This study was undertaken to measure the subfractions of high-density lipoprotein (HDL) in patients with diabetes or coronary artery disease and in normal control subjects.A new immunomagnetic separation technique was used to characterize the lipid profile in four groups: (1) control subjects, (2) patients with diabetes but no coronary artery disease ...
A, Rastogi +3 more
openaire +2 more sources
Determination of apolipoprotein A-I by kinetic nephelometry
Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1981Apolipoprotein A-I concentration in human serum was determined by kinetic nephelometry. Under optimal reaction conditions and within the normal physiological range the relation between apolipoprotein A-I concentration and measured rate units it approximately linear. The detection limit of the assay lies at 2 micrograms/ml.
N, Weinstock, M, Bartholome, D, Seidel
openaire +2 more sources
Repeated helical pattern in apolipoprotein-A-I
Nature, 1977THE binding of lipids into globules by the serum lipid-binding proteins depends on the unique structures of these proteins. Many have a high α helix content1–4 which is enhanced by the binding of lipid, and their amino acid sequences5–8 suggest that the helices are often ‘amphipathic’ with a long hydrophobic face buried in the lipid surface9,10 and an ...
openaire +2 more sources